Clinical Trials on Advanced/Recurrent Breast Cancer

Total 15724 results

AstraZeneca

Completed

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg (FINDER I)

Advanced Breast Cancer | Metastatic Breast Cancer

Japan
Immatics Biotechnologies GmbH

Recruiting

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

Germany
National Cancer Institute (NCI)

Completed

AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage...

United States
MedSIR
MacroGenics; Seagen Inc.

Withdrawn

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer (MARGARET)

Advanced Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer
University Hospital Tuebingen

Recruiting

Praegnant Breast Cancer: Early/Advanced/Metastatic (PRAEGNANT)

Advanced/Metastatic Breast Cancer | Breast Cancer (Early Breast Cancer)

Germany
Olema Pharmaceuticals, Inc.
Novartis

Recruiting

Phase 1b Combo w/ Ribociclib and Alpelisib

Advanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast Cancer

United States, Australia
NBE-Therapeutics AG
Cmed Clinical Services

Terminated

NBE-002 in Patients With Advanced Solid Tumors

Triple Negative Breast Cancer | Advanced Solid Tumor | Advanced Cancer

United States
National Cancer Institute (NCI)

Terminated

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Unspecified Adult Solid Tumor, Protocol Specific | HER2-positive Breast Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast... and other conditions

United States
Oslo University Hospital

Recruiting

Laparoscopic Robot-assisted Pelvic Exenteration for Pelvic Primary and Recurrent Cancers

Locally Advanced Pelvic Cancer That Require Pelvic Exenteration

Norway
Fudan University

Recruiting

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Advanced Breast Cancer | HR+/HER2- Breast Cancer

China
Hebei Medical University Fourth Hospital

Recruiting

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Advanced Breast Cancer | HER2-positive Breast Cancer

China
Spanish Breast Cancer Research Group
AstraZeneca

Recruiting

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain
Imperial College London
Cancer Research UK

Completed

A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer. (IRIS)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

United Kingdom
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

India
Center Trials & Treatment
BioGene Pharmaceutical

Withdrawn

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Breast Neoplasm | Advanced or Recurrent Solid Tumors

Albania
Hoffmann-La Roche

Withdrawn

A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Immatics Biotechnologies GmbH
Bristol-Myers Squibb

Recruiting

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

Germany
Tata Medical Center

Completed

Hypo-Fractionated Radiotherapy in Breast Cancer (HYPORT-B)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer

India
Pfizer

Completed

Palbociclib in Real World Practice

Advanced Breast Cancer | Metastatic Breast Cancer

United States, Canada
Royal Marsden NHS Foundation Trust
Pfizer; Hoffmann-La Roche

Recruiting

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM)

Advanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast Carcinoma

United States
Centre Leon Berard
GlaxoSmithKline

Recruiting

PREventing Second Cancers With DOSTARlimab (PREDOSTAR)

Recurrent Cancer | Second Cancer | Primary Cancer

France
Daiichi Sankyo

Recruiting

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Breast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast Cancer

China
Novartis Pharmaceuticals

Completed

A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors

Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology

China
Sun Pharma Advanced Research Company Limited

Terminated

A Study in Patients With Advanced Breast Cancer

Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

United States, India
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits

Malignant Neoplasm | Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Locally Advanced Malignant Neoplasm

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Metastatic Breast Cancer

China
Onco Medical Consult GmbH
Eli Lilly and Company; Institut fuer Frauengesundheit

Unknown

Implementing Patients´ Competence in Oral Breast Cancer Therapy (IMPACT)

Advanced Breast Cancer | Metastatic Breast Cancer
AstraZeneca

Completed

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg (FINDER II)

Advanced Breast Cancer | Metastatic Breast Cancer

Belgium, Turkey, Canada, Poland, Romania, Hungary, France, Czechia
Chang Gung Memorial Hospital
Eisai Co., Ltd.; Kaohsiung Breast Cancer Prevention and Education Society (KBCPES)

Unknown

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Advanced Breast Cancer | Metastatic Breast Cancer

Taiwan
Neovii Biotech

Terminated

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment

Advanced Breast Cancer | Metastatic Breast Cancer

Spain, Austria, France, Germany, Italy
Beijing GoBroad Hospital

Not yet recruiting

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Advanced Breast Cancer

China
Fudan University

Recruiting

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (BCTOP-L-M01)

Breast Cancer | Advanced Breast Cancer

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer (PERGIQUAL)

Advanced Breast Cancer

Italy
Novartis Pharmaceuticals

Recruiting

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment (ALPINIST)

Advanced Breast Cancer

India
Genor Biopharma Co., Ltd.

Recruiting

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Advanced Breast Cancer

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer

Advanced Breast Cancer
Fujian Medical University Union Hospital

Not yet recruiting

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

Advanced Breast Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance

Advanced Breast Cancer
European Institute of Oncology

Recruiting

Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients (VEX)

Advanced Breast Cancer

Italy
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Recruiting

The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial (plasmaMATCH)

Advanced Breast Cancer

United Kingdom
Spanish Breast Cancer Research Group
Novartis Pharmaceuticals; ETOP IBCSG Partners Foundation; Breast International...

Active, not recruiting

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (ALPHABET)

Advanced Breast Cancer

Spain, Netherlands, France, Italy, Austria, Switzerland
Novartis Pharmaceuticals

Terminated

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant (TELEPIK)

Advanced Breast Cancer

Sweden
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Advanced Breast Cancer

Japan
Shandong Luoxin Pharmaceutical Group Stock Co.,...

Completed

A Phase I Study of LX-039 Tablets

Advanced Breast Cancer

China

Clinical Trials on Advanced/Recurrent Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations